Asymmetry Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Asymmetry Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-69,124	Closed	-$1.31M	–	39
2017 Q4	$1.31M	Buy	+69,124	New	+$1.04M	1.78%	18
2016 Q3	–	Sell	-83,502	Closed	-$4.19M	–	22
2016 Q2	$4.19M	Buy	83,502 +42,216	+102%	+$2.25M	7.68%	5
2016 Q1	$2.21M	Sell	41,286 -34,000	-45%	-$1.99M	5.76%	8
2015 Q4	$4.94M	Buy	75,286 +27,201	+57%	+$1.68M	7.47%	6
2015 Q3	$2.71M	Buy	+48,085	New	+$3.12M	6.05%	7

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Asymmetry Capital Management's TEVA Position: Q1 2018 in Review

Asymmetry Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2018, closing a stake of 69,124 shares — an estimated $1.31M sold.

Asymmetry Capital Management first reported a position in TEVA in Q3 2015 and held it in 5 quarters. The position peaked at $4.94M in Q4 2015. 506 funds tracked by Wall St. Rank hold TEVA as of Q1 2018.

Asymmetry Capital Management reported no remaining Teva Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
Asymmetry Capital Management sold 69,124 Teva Pharmaceuticals shares in Q1 2018, an estimated $1.31M.
Asymmetry Capital Management first reported a position in Teva Pharmaceuticals in Q3 2015 and held it in 5 quarters.
Asymmetry Capital Management's Teva Pharmaceuticals position peaked at $4.94M in Q4 2015.
506 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2018.

Based on Asymmetry Capital Management's 13F filing for Q1 2018, filed 9 May 2018.